IMNM Q3 2024 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-18.4% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$51M-1736.2% margin

Net Income

-$47M-1618.6% margin

EPS (Diluted)

$-0.78

QoQ Revenue Growth

+23.1%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$36M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$257M

Total Liabilities

$42M

Stockholders' Equity

$215M

Cash & Equivalents

$156M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-18.4%
Gross Profit	$3M	$3M	-14.4%
Operating Income	-$51M	-$5M	-990.5%
Net Income	-$47M	-$4M	-984.0%